

**Appendix 4E**  
**Preliminary Final Report**  
**30 June 2019**

**AVITA MEDICAL LIMITED**  
 ABN 28 058 466 523

**Results for announcement to the market**

	<b>Movement</b>	<b>June 2019</b>	<b>June 2018</b>
<b>Financial Results</b>		<b>A\$</b>	<b>A\$</b>
Sale of goods	Up 543%	7,705,398	1,198,861
Other income	Down 8%	9,326,520	10,172,698
Loss for the period attributable to owners of the parent	Up 109%	34,603,141	16,519,155
Total comprehensive loss attributable to owners of the parent	Up 106%	32,819,919	15,955,876

<b>Dividends</b>	<b>Amount per Ordinary Security</b>	<b>Franked amount per security</b>
2018 interim dividend	Nil	Nil
2017 interim dividend	Nil	Nil

Record date for determining entitlements to interim dividends	N/A
---	-----

<b>Net Tangible Asset Backing</b>	<b>June 2019</b>	<b>June 2018</b>
Net tangible asset backing per ordinary security	A\$0.0161	A\$0.0149

**AVITA MEDICAL LIMITED**  
**CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME**  
**FOR THE YEAR ENDED 30 JUNE 2019**

	Note	2019	2018
<b>Continuing operations</b>			
Sale of goods	2	A\$ 7,705,398	A\$ 1,198,861
Cost of sales		(1,697,823)	(511,646)
<b>Gross profit</b>		<b>6,007,575</b>	<b>687,215</b>
BARDA income	2	8,259,152	10,104,081
Other income	2	1,067,368	68,617
<b>Total other income</b>		<b>9,326,520</b>	<b>10,172,698</b>
<b>Operating costs</b>			
Sales and marketing expenses		(17,576,754)	(8,936,441)
Corporate and administrative expenses		(15,398,176)	(5,360,553)
Product development expenses		(14,361,995)	(12,606,127)
Share-based payment expenses		(2,742,405)	(1,835,157)
Finance costs		(37,769)	(26,586)
<b>Total operating costs</b>		<b>(50,117,099)</b>	<b>(28,764,864)</b>
<b>Loss from continuing operations before income tax benefit</b>		<b>(34,783,004)</b>	<b>(17,904,951)</b>
Income tax benefit (net)		179,863	1,385,796
<b>Loss for the period</b>		<b>(34,603,141)</b>	<b>(16,519,155)</b>
<b>Other comprehensive income</b>			
<i>Items that may be reclassified subsequently to profit and loss:</i>			
Foreign currency translation		1,783,222	563,279
<b>Other comprehensive income for the period, net of tax</b>		<b>1,783,222</b>	<b>563,279</b>
<b>Total other comprehensive loss for the period</b>		<b>A\$ (32,819,919)</b>	<b>A\$ (15,955,876)</b>
Loss for the period attributable to owners of the parent		(34,603,141)	(16,519,155)
<b>Total comprehensive loss attributable to owners of the parent</b>		<b>A\$ (32,819,919)</b>	<b>A\$ (15,955,876)</b>
Basic loss per share attributable to ordinary equity holders of the parent		A\$ (2.73) cents	A\$ (1.77) cents
Diluted loss per share attributable to ordinary equity holders of the parent		A\$ (2.73) cents	A\$ (1.77) cents

The accompanying notes form part of the consolidated financial statements.

**AVITA MEDICAL LIMITED**  
**CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**  
**AS AT 30 JUNE 2019**

	Notes	2019	2018
<b>ASSETS</b>			
<b>Current assets</b>			
Cash and cash equivalents		A\$ 28,983,491	A\$ 14,825,532
Trade and other receivables	3	2,980,102	5,437,357
Prepayments and other assets		1,557,525	855,716
Inventories	4	1,057,764	1,155,826
<b>Total current assets</b>		<b>34,578,882</b>	<b>22,274,431</b>
<b>Non-current assets</b>			
Plant and equipment		1,838,515	742,583
Patents-in-progress		320,676	-
<b>Total non-current assets</b>		<b>2,159,191</b>	<b>742,583</b>
<b>TOTAL ASSETS</b>		<b>A\$ 36,738,073</b>	<b>A\$ 23,017,014</b>
<b>LIABILITIES</b>			
<b>Current liabilities</b>			
Trade and other payables		5,633,562	3,487,582
Provisions		650,359	395,535
<b>Total current liabilities</b>		<b>6,283,921</b>	<b>3,883,117</b>
<b>Non-current liabilities</b>			
Finance lease		54,057	134,338
<b>Total non-current liabilities</b>		<b>54,057</b>	<b>134,338</b>
<b>TOTAL LIABILITIES</b>		<b>A\$ 6,337,978</b>	<b>A\$ 4,017,455</b>
<b>NET ASSETS</b>		<b>A\$ 30,400,095</b>	<b>A\$ 18,999,559</b>
<b>EQUITY</b>			
Equity attributable to equity holders of the parent:			
Contributed equity	5	204,279,078	162,801,028
Accumulated losses		(183,196,020)	(148,592,879)
Reserves		9,317,037	4,791,410
<b>TOTAL EQUITY</b>		<b>A\$ 30,400,095</b>	<b>A\$ 18,999,559</b>

The accompanying notes form part of the consolidated financial statements.

**AVITA MEDICAL LIMITED**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**FOR THE YEAR ENDED 30 JUNE 2019**

	<b>2019</b>	<b>2018</b>
<b>Cash flows from operating activities</b>		
Payments to suppliers and employees	A\$ (47,030,980)	A\$ (25,681,347)
Interest paid	-	(26,586)
BARDA receipts and other income received	10,827,561	8,141,207
Receipts from customers	5,826,634	1,129,046
R&D tax refund received	2,440,803	-
Interest received	450,323	65,656
<b>Net cash flows used in operating activities</b>	<b>(27,485,659)</b>	<b>(16,372,024)</b>
<b>Cash flows from investing activities</b>		
Payments for plant and equipment	(1,473,934)	(498,749)
Payments for intellectual property	(320,676)	-
<b>Net cash flows used in investing activities</b>	<b>(1,794,610)</b>	<b>(498,749)</b>
<b>Cash flows from financing activities</b>		
Proceeds from issuance of shares and options	45,036,886	29,760,563
Proceeds from exercise of share options	452,809	-
Capital raising expenses	(4,192,519)	(1,825,643)
<b>Net cash flows provided by financing activities</b>	<b>41,297,176</b>	<b>27,934,920</b>
<b>Net increase in cash and cash equivalents</b>	<b>12,016,907</b>	<b>11,064,147</b>
<b>Cash and cash equivalents at beginning of period</b>	<b>14,825,532</b>	<b>3,790,491</b>
Impact of foreign exchange	2,141,052	(29,106)
<b>Cash and cash equivalents at end of period</b>	<b>A\$ 28,983,491</b>	<b>A\$ 14,825,532</b>

The accompanying notes form part of the consolidated financial statements.

**AVITA MEDICAL LIMITED**  
**CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY**  
**FOR THE YEAR ENDED 30 JUNE 2019**

	Contributed equity	Accumulated losses	Share-based payment reserve	Foreign currency translation reserve	Total
<b>At 1 July 2018</b>	<b>A\$ 162,801,028</b>	<b>A\$ (148,592,879)</b>	<b>A\$ 4,505,148</b>	<b>A\$ 286,262</b>	<b>A\$ 18,999,559</b>
Loss for the period	-	(34,603,141)	-	-	(34,603,141)
Other comprehensive income					
Foreign currency translation	-	-	-	1,783,222	1,783,222
<b>Total comprehensive loss for the year</b>	<b>-</b>	<b>(34,603,141)</b>	<b>-</b>	<b>1,783,222</b>	<b>(32,819,919)</b>
<i>Transactions with owners in their capacity as owners</i>					
Expired options	-	-	(32,362)	-	(32,362)
Share based payments	-	-	2,774,767	-	2,774,767
New shares	45,580,570	-	-	-	45,580,570
Cost of share placement	(4,102,520)	-	-	-	(4,102,520)
<b>Balance at 30 June 2019</b>	<b>A\$ 204,279,078</b>	<b>A\$ (183,196,020)</b>	<b>A\$ 7,247,553</b>	<b>A\$ 2,069,484</b>	<b>A\$ 30,400,095</b>

The accompanying notes form part of the consolidated financial statements.

**AVITA MEDICAL LIMITED**  
**CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY**  
**FOR THE YEAR ENDED 30 JUNE 2018**

	Contributed equity	Accumulated losses	Share-based payment reserve	Foreign currency translation reserve	Total
<b>At 1 July 2017</b>	<b>A\$ 134,806,022</b>	<b>A\$ (132,218,352)</b>	<b>A\$ 2,811,179</b>	<b>A\$ (277,017)</b>	<b>A\$ 5,121,832</b>
Loss for the period	-	(16,519,155)	-	-	(16,519,155)
Other comprehensive income					
Foreign currency translation	-	-	-	563,279	563,279
<b>Total comprehensive loss for the year</b>	<b>-</b>	<b>(16,519,155)</b>	<b>-</b>	<b>563,279</b>	<b>(15,955,876)</b>
<i>Transactions with owners in their capacity as owners:</i>					
Expired options	-	141,188	(141,188)	-	-
Forfeiture options	-	3,440	(31,832)	-	(28,392)
Share based payments	-	-	1,866,989	-	1,866,989
New shares	29,846,859	-	-	-	29,846,859
Cost of share placement	(1,851,853)	-	-	-	(1,851,853)
<b>Balance at 30 June 2018</b>	<b>A\$ 162,801,028</b>	<b>A\$ (148,592,879)</b>	<b>A\$ 4,505,148</b>	<b>A\$ 286,262</b>	<b>A\$ 18,999,559</b>

The accompanying notes form part of the consolidated financial statements.

**AVITA MEDICAL LIMITED  
NOTES TO THE PRELIMINARY FINAL REPORT  
FOR THE YEAR ENDED 30 JUNE 2019**

**1. BASIS OF PREPARATION AND ACCOUNTING POLICIES**

**Basis of Preparation**

Avita Medical Limited (“Company”) is incorporated in Australia and is a for-profit entity for purposes of preparing the consolidated financial statements. The financial statements for the consolidated entity which consists of Avita Medical Limited and its subsidiaries (collectively referred to as the “Group”) for the year ended 30 June 2019 were authorized for issue by the Board of Directors on 30 August 2019.

The consolidated financial statements are general purpose consolidated financial statements that:

- have been prepared in accordance with the requirements of the *Corporations Act 2001* of International Financial Reporting Standards (“IFRS”);
- include the assets and liabilities of the Group as of 30 June 2019 and the results of the subsidiaries for the year then ended. Inter-entity transactions with, or between, subsidiaries are eliminated in full on consolidation;
- have been prepared on a historical cost basis;
- are measured and presented in Australian dollars which is ASX’s functional and presentation currency.

The preliminary financial report does not include all notes of the type normally included within the annual financial report and therefore cannot be expected to provide a full understanding of the financial performance, financial position and financing and investing activities of the consolidated entity as the full financial report. Accordingly, this report is to be read in conjunction with the accompanying notes, the 2018 Annual Report, the 2018 Annual Financial Statements and any public announcements made by Avita Medical Limited in accordance with the continuous disclosure obligations of the *ASX listing rules*.

This financial report has been prepared on the going concern basis. The accounting policies have been applied consistently throughout the Group for the purposes of preparation of the consolidated financial statements.

**Commentary on the results for the period**

Avita Medical Limited and its subsidiaries are a regenerative medicine company with a technology platform designed to address unmet medical needs in patients with burns, chronic wounds, and aesthetics indications. The Company’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. The Company’s medical devices work by preparing a Regenerative Epidermal Suspension (RES™), an autologous suspension comprised of the patient’s own skin cells that are necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment. The first medical device based on the RES technology, the RECELL® System, was approved for sale in the U.S. for the treatment of acute thermal burns in patients 18 and older by the Food and Drug Administration (FDA) in September 2018. The Company initiated its U.S. national market launch of the RECELL System in January 2019, although it did commence commercial shipments in the U.S. during the half-year ended 31 December 2018 in response to pre-launch demand from burn centers. The RECELL System is also sold on a limited basis in certain regions of the world in which the products are approved for sale, including Australia, China and Europe.

Sale of goods of the RECELL System totaled \$7,705,398 for the year ended 30 June 2019, an increase of \$6,506,537 or 543% over the \$1,198,861 recognized during fiscal 2018. The majority of the current fiscal year increase in sales occurred in the U.S. as a result of the September 2018 FDA approval and commencement of the U.S. national market launch of the RECELL System in January 2019. U.S. sales during the fiscal year ended 30 June 2019 totaled \$6,214,660 compared to zero in the prior fiscal year. Gross margin for the fiscal year ended 30 June 2019 was 78% compared to 57% for the same period in 2018, and management expects gross margins to further increase as sales ramp up within the U.S.

Other income totaled \$9,326,520 for the year ended 30 June 2019, a decrease of \$846,178 or 8% over the \$10,172,698 recognized during fiscal 2018. As in prior periods, the majority of other income consisted of funding from the Biomedical Advanced Research and Development Authority (BARDA), under the Assistant Secretary for Preparedness and Response, within the U.S. Department of Health and Human Services, under ongoing USG Contract No. HHSO100201500028C. Under the BARDA contract, income of \$8,259,152 was recognized during the year ended 30 June 2019 compared to income of \$10,104,081 for

fiscal 2018. The decrease was the result of wind-down of certain activities associated with supporting the U.S. FDA approval of the RECELL System as well as the compassionate use and continued access programs.

Operations for the first half of the fiscal year ended 30 June 2019 were focused primarily on preparation for the January 2019 U.S. market launch of the RECELL System. Sales and marketing expenses for the year ended 30 June 2019 totaled \$17,576,754, an increase of \$8,640,313 or 97% over the \$8,936,441 recognized during fiscal 2018. This increase was primarily attributed to the recruitment, hiring and training of a U.S. sales force and the associated product launch sales and marketing materials and activities. Product development expenses for the fiscal 2019 totaled \$14,361,995 an increase of \$1,755,868 or 14% over the \$12,606,127 recognized during fiscal 2018. Corporate and administrative expenses totaled \$15,398,176 for the year ended 30 June 2019, an increase of \$10,037,623 or 187% over the \$5,360,553 recognized during fiscal 2018. As the result of investments in commercial, manufacturing, and system capabilities for the U.S. market launch of the RECELL System and related initiatives, operating costs for the year ended 30 June 2019 totaled \$50,117,099, a \$21,352,235 or 74% increase over the \$28,764,864 incurred during fiscal 2018 and were in line with management expectations.

Net comprehensive loss after tax for the fiscal year ended 30 June 2019 was \$32,819,919, an increase of \$16,864,043 or 106% over \$15,955,876 recognized during fiscal 2018. The increase in net comprehensive loss was driven by the higher operating costs described above, partially offset by the higher sale of goods during the fiscal year. As a result of the U.S. national launch of the RECELL System in January 2019, and the expansion of research and development, operating expenses will increase in future periods. These expenses are expected to be partially offset by increased sales of goods and income under the BARDA contract.

During the year ended 30 June 2019, the net cash provided by the issuance of shares and employee stock options exercised were \$40,844,367 and \$452,809, respectively. Cash and cash equivalents held at 30 June 2019 was \$28,983,491 an increase of \$14,157,959 or 95% over \$14,825,532 recognized during fiscal 2018. The increase in cash and cash equivalents was driven by the institutional placement of shares and employee stock options exercised, partially offset by the operating costs during the fiscal year. Future cash requirement will be dependent upon the success of AVITA Medical's efforts to commercialize the RECELL System, particularly in the U.S., and the timing and magnitude of clinical and other research and development programs the Company elects to undertake to expand its product pipeline. Until such time that the Company generates sufficient cash flow from operations, it expects to fund its future cash requirements through a combination of the issuance of shares and possible debt financing.



**AVITA MEDICAL LIMITED**  
**NOTES TO THE PRELIMINARY FINAL REPORT**  
**FOR THE YEAR ENDED 30 JUNE 2019**

**2. REVENUES AND EXPENSES**

**Revenue and Expenses from Continuing Operations**

	<b>2019</b>	<b>2018</b>
<b>(a) Revenue</b>		
Sale of goods	A\$ 7,705,398	A\$ 1,198,861
<b>(b) Other income</b>		
BARDA income	8,259,152	10,104,081
Other income	1,067,368	68,617
<b>Total other income</b>	<b>A\$ 9,326,520</b>	<b>A\$ 10,172,698</b>
<b>(c) Employee benefits expense</b>		
Salaries and wages	A\$ 15,472,511	A\$ 8,057,869
Share-based expenses	2,742,405	1,835,157
Defined contribution superannuation expense	831,558	374,435
	<b>A\$ 19,046,474</b>	<b>A\$ 10,267,461</b>

**3. CURRENT ASSETS - TRADE AND OTHER RECEIVABLES**

	<b>2019</b>	<b>2018</b>
Trade receivables	A\$ 2,143,889	A\$ 263,421
Allowance for doubtful debts	(25,155)	(23,452)
	2,118,734	239,969
R & D tax claim	179,863	2,434,430
BARDA and other receivables	681,505	2,762,958
<b>Carrying amount of trade and other receivables</b>	<b>A\$ \$2,980,102</b>	<b>A\$ 5,437,357</b>

AVITA MEDICAL LIMITED  
 NOTES TO THE PRELIMINARY FINAL REPORT  
 FOR THE YEAR ENDED 30 JUNE 2019

4. CURRENT ASSETS - INVENTORIES

	Consolidated	
	2019	2018
Raw materials and components at cost	A\$ 869,016	A\$ 778,947
Finished goods at cost	188,748	376,879
<b>Total inventories at cost</b>	<b>A\$ 1,057,764</b>	<b>A\$ 1,155,826</b>

5. CONTRIBUTED EQUITY

	2019	2018
<i>Ordinary shares</i>		
Issued and fully paid	A\$ 204,279,078	A\$ 162,801,028
	<b>A\$ 204,279,078</b>	<b>A\$ 162,801,028</b>

***Movement in ordinary shares on issue***

	Number of shares	Amount
At 1 July 2018	1,277,378,325	A\$ 162,801,028
New shares	593,921,250	45,580,570
Capital issue costs	-	(4,102,520)
<b>At 30 June 2019</b>	<b>1,871,299,575</b>	<b>A\$ 204,279,078</b>

**AVITA MEDICAL LIMITED  
NOTES TO THE PRELIMINARY FINAL REPORT  
FOR THE YEAR ENDED 30 JUNE 2019**

**6. SUBSEQUENT EVENTS**

On July 19, 2019, AVITA confidentially submitted a draft registration statement on Form 20-F under the Securities Exchange Act of 1934 with the Securities and Exchange Commission relating to the proposed registration in the United States of its class of American Depositary Shares representing ordinary shares of the Company. This disclosure does not constitute an offer to sell, or the solicitation of an offer to buy, any securities of the Company. In connection with the registration of such class of securities, on 2 August 2019, the Company applied for listing on NASDAQ. There is no guarantee the Company's efforts will be successful and that the Company may abandon its efforts to register the class of shares and the NASDAQ application at any time at its sole discretion.

**Compliance statement**

- 1 This report has been prepared in accordance with AASB Standards, other AASB authoritative pronouncements and IFRS.
- 2 This report, and the accounts upon which the report is based (if separate), use the same accounting policies.
- 3 This report does give a true and fair view of the matters disclosed
- 4 This report is based on accounts to which one of the following applies.  
(Tick one)
 

<input type="checkbox"/>	The accounts have been audited.	<input type="checkbox"/>	The accounts have been subject to review.
<input checked="" type="checkbox"/>	The accounts are in the process of being audited or subject to review.	<input type="checkbox"/>	The accounts have <i>not</i> yet been audited or reviewed.
- 5 The entity has a formally constituted audit committee.

Sign here:

Date: 30 August 2019

*Timothy Rooney*

**Timothy Rooney**  
**Chief Administrative Officer and Interim Chief Financial Officer**